Danish dermatology specialist LEO Pharma could be just weeks away from EU approval for delgocitinib, a treatment for chronic hand eczema (CHE) considered to be its top pipeline prospect.

Germany has become the debut market for LEO Pharma's Anzupgo, the first topical treatment specifically approved for chronic hand eczema (CHE). The launch of pan-JAK inhibitor Anzupgo (delgocitinib ...